VIEWPOINTS

Reimagining Migraine Treatment: Alon Ironi of Theranica on Nerivio’s Journey to Nationwide Coverage

Shots: What started as a father’s determination to find a better solution has grown into a widely reimbursed therapy. Along the way, strong clinical evidence, early physician support, and carefully designed payer pilots helped unlock nationwide coverage, reaching nearly 130 million lives across Blue Cross Blue Shield plans. In this conversation, Alon explains how Nerivio’s dual acute and preventive…

March 23, 2026

From Denials to Decisions: Dr. Wael Khouli of Authsnap on AI-Powered Healthcare Appeals

Shots: Did you know that nearly 15–20% of healthcare claims in the U.S. are denied on first submission, creating billions of dollars in administrative costs and forcing providers into complex, time-consuming appeals processes that strain revenue cycles, clinical staff, and patient care continuity? Authsnap is an AI healthcare technology company helps providers manage insurance denials and…

March 16, 2026

Bridging Innovation and Clinical Reality: Shalabh Gupta, CEO of Unicycive Therapeutics, on the Future of Biotech

Shots Cross-industry lessons from technology, design thinking, and startups can reshape drug development by encouraging faster iteration, disciplined decision-making, and a stronger focus on real patient needs, unlocking innovations that traditional biotech models may overlook. Clinical experience and thoughtful engagement with the U.S. Food and Drug Administration highlight the importance of patient insights, transparent…

March 9, 2026

Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision

Shots: The EU approval of Vueway for neonates, infants, and toddlers is a milestone for pediatric imaging as it allows high-quality MRI imaging at half the GBCA dose, supporting reduced gadolinium exposure in vulnerable young patients Vueway’s gadopiclenol demonstrates safety and diagnostic performance by offering high stability, low dissociation risk, and 2.5–4× greater relaxivity than other macrocyclic GBCAs, enabling effective imaging…

March 2, 2026

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001

Shots: GH001, an inhaled formulation of mebufotenin, is emerging as a highly differentiated therapy for treatment-resistant depression, delivering ultra-rapid and profound symptom improvement – patients come to the clinic depressed and many leave in remission already on the same day. Long term, in a Phase 2b trial, 73% of patients who completed six months were in remission—substantially higher than the…

February 23, 2026

Transforming Lupus Management: Caterina Brindicci Shares AstraZeneca’s Approach to Patient-Focused Care

Shots: TULIP-SC full results reinforce efficacy and remission potential with subcutaneous Saphnelo, showing higher disease activity reduction (56.2% vs 34% placebo at Week 52), improved BICLA response, DORIS-defined remission, and reduced oral corticosteroid use, consistent with the IV formulation Self-administration expands access and adherence, offering flexible at-home or clinic dosing, supporting earlier biologic intervention and steroid…

February 18, 2026

Powering the Next Era of Animal Health: Gary Yang on CPBIO’s Global Strategy

Shots: CPBIO’s expanding global footprint is powered by a science-led strategy that connects innovation, partnerships, and emerging market growth with a core goal: turning evidence-based R&D into practical solutions that improve livestock productivity, resilience, and sustainability. The company delivers species-specific solutions across poultry, swine, ruminants, and aquaculture while following a unified R&D philosophy focused on…

February 16, 2026

Bringing Lupus Care Closer to Patients: Caterina Brindicci on AstraZeneca’s Next Chapter in Immunology

Shots: AstraZeneca’s patient-focused immunology vision is reinforced by the EU approval of subcutaneous, self-administered Saphnelo (anifrolimab), offering people with SLE a more convenient option that reduces treatment burden, supports earlier biologic use, and advances the goal of remission beyond symptom control The new formulation is expected to improve access, uptake, and adherence while easing infusion capacity constraints, with regulatory…

February 4, 2026

Pictor Labs at SITC 2025: Megan Rothney on How ClearStain Is Transforming Molecular Sequencing and Precision Oncology

Shots: ClearStain debuted at SITC 2025 as a workflow-changing innovation, delivering high-quality virtual H&E images from unstained slides to improve tumor identification, reduce sequencing failures, preserve tissue, and accelerate molecular and precision oncology workflows By enabling direct visualization and annotation of the exact tissue destined for sequencing, ClearStain helps pathologists and molecular labs maximize tumor purity, minimize impurities,…

January 19, 2026

Inside Anavex’s Alzheimer’s Strategy: Dr. Christopher Missling on Blarcamesine, SIGMAR1, and Precision Medicine

Shots: Neurodegenerative care is at a pivotal inflection point, shifting from symptomatic relief to strategies that restore cellular resilience. Blarcamesine (ANAVEX 2-73) advances this upstream approach by activating SIGMAR1 to rebalance autophagy, targeting a core driver of neurodegeneration Phase IIb/III findings demonstrated a statistically significant slowing of cognitive decline, with the most pronounced benefit seen in patients carrying the…

December 22, 2025